Estimating scenarios for survival time in men starting systemic therapies for castration-resistant prostate cancer: A systematic review of randomised trials

European Journal of Cancer

Volumn 50, Issue 11, 2014, Pages 1916-1924

  West, T A ^a   Kiely, B E ^b,c   Stockler, M R ^a,b,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ANZAC Research Institute   (Australia)

Author keywords

Chemotherapy; Prognosis; Prostate cancer; Survival time

Indexed keywords

ABIRATERONE; ANTHRACYCLINE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; BEVACIZUMAB; BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CABAZITAXEL; CALCITRIOL; CORTICOSTEROID; DIETHYLSTILBESTROL; DOCETAXEL; ENZALUTAMIDE; ESTRAMUSTINE; PROSTATE SPECIFIC ANTIGEN; SATRAPLATIN; SIPULEUCEL T; SURAMIN; VINCA ALKALOID;

ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; FOLLOW UP; HUMAN; MALE; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL TIME; SYSTEMATIC REVIEW; SYSTEMIC THERAPY;

CHEMOTHERAPY; PROGNOSIS; PROSTATE CANCER; SURVIVAL TIME;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; MALE; PROGNOSIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84902296157     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.04.004     Document Type: Article

References (41)

1. J. Ferlay, H.R. Shin, F. Bray, D. Forman, C. Mathers, and D.M. Parkin Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Int J Cancer 127 12 2010 2893 2917
2. M. Kirby, C. Hirst, and E.D. Crawford Characterising the castration-resistant prostate cancer population: a systematic review Int J Clin Pract 65 11 2011 1180 1192
3. D. Mukherji, A. Eichholz, and J.S. De Bono Management of metastatic castration-resistant prostate cancer: recent advances Drugs 72 8 2012 1011 1028
4. P.N. Butow, S. Dowsett, R. Hagerty, and M.H. Tattersall Communicating prognosis to patients with metastatic disease: what do they really want to know? Support Care Cancer 10 2 2002 161 168
5. R.G. Hagerty, P.N. Butow, P.M. Ellis, S. Dimitry, and M.H. Tattersall Communicating prognosis in cancer care: a systematic review of the literature Ann Oncol 16 7 2005 1005 1053
6. S. Innes, and S. Payne Advanced cancer patients' prognostic information preferences: a review Palliat Med 23 1 2009 29 39
7. E.A. Lobb, P.N. Butow, D.T. Kenny, and M.H. Tattersall Communicating prognosis in early breast cancer: do women understand the language used? Med J Aust 171 6 1999 290 294
8. M.R. Stockler, M.H. Tattersall, M.J. Boyer, S.J. Clarke, P.J. Beale, and R.J. Simes Disarming the guarded prognosis: predicting survival in newly referred patients with incurable cancer Br J Cancer 94 2 2006 208 212
9. B.E. Kiely, M. Alam, P. Blinman, M.H. Tattersall, and M.R. Stockler Estimating typical, best-case and worst-case life expectancy scenarios for patients starting chemotherapy for advanced non-small-cell lung cancer: a systematic review of contemporary randomized trials Lung cancer 77 3 2012 537 544
10. B.E. Kiely, Y.Y. Soon, M.H.N. Tattersall, and M.R. Stockler How Long Have I Got? Estimating Typical, Best-Case, and Worst-Case Scenarios for Patients Starting First-Line Chemotherapy for Metastatic Breast Cancer: A Systematic Review of Recent Randomized Trials J Clin Oncol 29 4 2011 456 463
11. B.E. Kiely, G. McCaughan, S. Christodoulou, P.J. Beale, P. Grimison, and J. Trotman et al. Using scenarios to explain life expectancy in advanced cancer: attitudes of people with a cancer experience Support Care Cancer 21 2 2013 369 376
12. M. Shelley, C. Harrison, B. Coles, J. Staffurth, T.J. Wilt, and M.D. Mason Chemotherapy for hormone-refractory prostate cancer Cochrane Database Syst Rev 4 2006 CD005247
13. N. Shore, M. Mason, and T.M. de Reijke New developments in castrate-resistant prostate cancer BJU Int 109 Suppl. 6 2012 22 32
14. UN-SCAN-IT. Orem, Utah, United States, Silk Scientific, 2012.
15. R.P. Abratt, D. Brune, M.A. Dimopoulos, J. Kliment, J. Breza, and F.P. Selvaggi et al. Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer Ann Oncol 15 11 2004 1613 1621
16. T.M. Beer, C.W. Ryan, P.M. Venner, D.P. Petrylak, G.S. Chatta, and J.D. Ruether et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators J Clin Oncol 25 6 2007 669 674
17. D.R. Berthold, G.R. Pond, F. Soban, R. de Wit, M. Eisenberger, and I.F. Tannock Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study J Clin Oncol 26 2 2008 242 245
18. J.S. de Bono, S. Oudard, M. Ozguroglu, S. Hansen, J.P. Machiels, and I. Kocak et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 9747 2010 1147 1154
19. D.S. Ernst, I.F. Tannock, E.W. Winquist, P.M. Venner, L. Reyno, and M.J. Moore et al. Randomized, double-blind, controlled trial of mitoxantrone/ prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain J Clin Oncol 21 17 2003 3335 3342
20. K. Fizazi, H.I. Scher, A. Molina, C.J. Logothetis, K.N. Chi, and R.J. Jones et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study Lancet Oncol 13 10 2012 983 992
21. C.S. Higano, P.F. Schellhammer, E.J. Small, P.A. Burch, J. Nemunaitis, and L. Yuh et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer Cancer 115 16 2009 3670 3679
22. G. Hudes, L. Einhorn, E. Ross, A. Balsham, P. Loehrer, and H. Ramsey et al. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: a Hoosier Oncology Group and Fox Chase Network phase III trial J Clin Oncol 17 10 1999 3160 3166
23. P.W. Kantoff, S. Halabi, M. Conaway, J. Picus, J. Kirshner, and V. Hars et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study J Clin Oncol 17 8 1999 2506 2513
24. P.W. Kantoff, C.S. Higano, N.D. Shore, E.R. Berger, E.J. Small, and D.F. Penson et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 5 2010 411 422
25. P.L. Kellokumpu-Lehtinen, U. Harmenberg, T. Joensuu, R. McDermott, P. Hervonen, and C. Ginman et al. 2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial Lancet Oncol 14 2 2013 117 124
26. W.K. Kelly, S. Halabi, M. Carducci, D. George, J.F. Mahoney, and W.M. Stadler et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401 J Clin Oncol 30 13 2012 1534 1540
27. J.B. Nelson, K. Fizazi, K. Miller, C. Higano, J.W. Moul, and H. Akaza et al. Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone Cancer 118 22 2012 5709 5718
28. J.B. Nelson, W. Love, J.L. Chin, F. Saad, C.C. Schulman, and D.J. Sleep et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer Cancer 113 9 2008 2478 2487
29. D.W. Newling, S.D. Fossa, U.W. Tunn, K.H. Kurth, M. de Pauw, and R. Sylvester Mitomycin C versus estramustine in the treatment of hormone resistant metastatic prostate cancer: the final analysis of the European Organization for Research and Treatment of Cancer, genitourinary group prospective randomized phase III study (30865) J Urol 150 6 1993 1840 1844
30. D.P. Petrylak, C.M. Tangen, M.H. Hussain, P.N. Lara Jr., J.A. Jones, and M.E. Taplin et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 15 2004 1513 1520
31. C.J. Ryan, M.R. Smith, J.S. de Bono, A. Molina, C.J. Logothetis, and P. de Souza et al. Abiraterone in metastatic prostate cancer without previous chemotherapy N Engl J Med 368 2 2013 138 148
32. H.I. Scher, K. Fizazi, F. Saad, M.-E. Taplin, C.N. Sternberg, and K. Miller et al. Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 367 13 2012 1187 1197
33. H.I. Scher, X. Jia, K. Chi, R. de Wit, W.R. Berry, and P. Albers et al. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer J Clin Oncol 29 16 2011 2191 2198
34. J. Shamash, T. Powles, S.J. Sarker, A. Protheroe, N. Mithal, and R. Mills et al. A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred Diethylstilbestrol Br J Cancer 104 4 2011 620 628
35. E.J. Small, S. Halabi, M.J. Ratain, G. Rosner, W. Stadler, and D. Palchak et al. Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480 J Clin Oncol 20 16 2002 3369 3375
36. C.N. Sternberg, D.P. Petrylak, O. Sartor, J.A. Witjes, T. Demkow, and J.-M. Ferrero et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial J Clin Oncol 27 32 2009 5431 5438
37. I.F. Tannock, D. Osoba, M.R. Stockler, D.S. Ernst, A.J. Neville, and M.J. Moore et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points J Clin Oncol 14 6 1996 1756 1764
38. R.G. Hagerty, P.N. Butow, P.M. Ellis, E.A. Lobb, S.C. Pendlebury, and N. Leighl et al. Communicating with realism and hope: incurable cancer patients' views on the disclosure of prognosis J Clin Oncol 23 6 2005 1278 1288
39. A.J. Armstrong, E.S. Garrett-Mayer, Y.C. Yang, R. de Wit, I.F. Tannock, and M. Eisenberger A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis Clin Cancer Res 13 21 2007 6396 6403
40. S. Halabi, E.J. Small, P.W. Kantoff, M.W. Kattan, E.B. Kaplan, and N.A. Dawson et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer J Clin Oncol 21 7 2003 1232 1237
41. O. Smaletz, H.I. Scher, E.J. Small, D.A. Verbel, A. McMillan, and K. Regan et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration J Clin Oncol 20 19 2002 3972 3982